Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Oct 22 - Oct 27
At the higher doses, results were very consistent: All participants lost at least 5% of their body weight Around 3 in 4 lost 15% or more With placebo, only around 1 in 4 lost 5% or more Phase 3 update (TRIUMPH-4, 68 weeks, topline results) In December 2025 , Eli Lilly shared early (topline) results from a larger phase 3 study (TRIUMPH-4)
- **Curb appetite:** Helping individuals feel full, potentially leading to reduced food intake
Risk of peripheral neuropathy with prolonged high-dose B6 Pain reduction: Within 3-5 doses Improved sensation: 2-4 weeks Nerve conduction: 6-8 weeks for measurable changes Maximum benefit: After 3 months of regular therapy Effects are cumulative and dose-dependent
Age on your terms
How is payer appetite to cover obesity medications changing, and how does insurance coverage impact patient/provider choice of medication
US$ 24.45
.png/:/rs=w:400,cg:true,m)
US$ 21.89
US$ 25.38
US$ 25.73
US$ 22.29
US$ 20.62
US$ 25.07
US$ 27.01
US$ 20.47
US$ 26.74
US$ 26.06
